Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success

20-Sep-2023 - Merck announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., ...

Merck and Artios will conduct collaborative research

Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology

03-Dec-2020 - Merck and Artios Pharma Limited, a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs. “Our platform has ...

Merck Licenses Four Oncology Research and Development Programs from Vertex

Vertex receives upfront payment of $230 million plus royalties on future sales

12-Jan-2017 - Merck announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Inc. for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.“With this strategic deal we ...

Merck and Pfizer to present Avelumab data in seven different cancers

Data featured contributes to growing understanding of the potential role of avelumab in treating a broad range of cancers

20-May-2016 - Merck and Pfizer announced that avelumab presentations across seven different tumor types, including two oral presentations, will be featured at the American Society of Clinical Oncology (ASCO) Annual Meeting. The avelumab presentations, from the rapidly accelerating JAVELIN clinical development ...

Merck Appoints Maya Martinez-Davis as Global Head of Oncology

18-Apr-2016 - Merck announces the appointment of Maya Martinez-Davis (46), as Global Head of Oncology Franchise for its biopharma business. She will report to Rehan Verjee, Chief Marketing and Strategy Officer of Merck’s Healthcare business sector, and will be based in Billerica, Massachusetts, USA. In her new ...

Merck and Pfizer Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

22-Apr-2015 - Merck and Pfizer announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV ...

Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy

02-Apr-2015 - Merck Serono and Intrexon Corporation announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono’s comprehensive, science-driven strategy to develop ...

Lead Discovery Center and Merck KGaA Enter Collaboration for the Discovery of Anti-Cancer Compounds

Research collaboration may realize the potential of kinase inhibitors as a means for cancer treatments in the future

24-Jan-2011 - The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments. The collaboration is supported by the German ...

Merck KGaA: Erbitux Long-Term Survival Benefit for mCRC Patients Confirmed With FOLFOX

21-Jan-2011 - Merck KGaA highlighted a further analysis of the large randomized Phase II OPUSa study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with ...